Clinical Trial Detail

NCT ID NCT02981303
Title Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Biothera
Indications

triple-receptor negative breast cancer

melanoma

Therapies

Pembrolizumab + PGG beta-glucan

Age Groups: adult senior

Additional content available in CKB BOOST